Update on PROMETRIUM® (progesterone) 

Kirkland (Quebec) – November 13, 2026 – Nothing is more important to Organon than the safety of the patients who use our products. PROMETRIUM® (progesterone) has been a treatment option for women for more than 30 years and continues to be manufactured in accordance with all applicable quality standards, regulatory requirements, and current Good Manufacturing Practices (cGMP). 

We confirm that, as part of our ongoing safety and quality processes, we have received reports regarding PROMETRIUM®. We take these reports seriously and are currently investigating the information provided in accordance with our established procedures and applicable Canadian regulatory requirements, which is still ongoing. Every single adverse event report and product quality complaint received by Organon is documented, assessed, and investigated. We have communicated the reports with Health Canada and are following applicable regulatory requirements

Patients may continue to use PROMETRIUM® in accordance with the Product Monograph. There is currently no market action, including a recall, affecting PROMETRIUM®.

PROMETRIUM® is indicated for women with an intact uterus as an adjunct to postmenopausal estrogen replacement therapy to significantly reduce the risk of endometrial hyperplasia and carcinoma.1    

 Guidance for Patients 

To ensure appropriate use of the product, patients are instructed to use PROMETRIUM® in accordance with the Product Monograph, including, without limitation, taking capsules by mouth and swallowing them whole. Capsules should not be crushed, chewed, pierced, or opened prior to administration. In addition, PROMETRIUM® should be stored at temperatures between 15°C and 30°C and protected from light. 

 About Pharmacovigilance and Monitoring in Canada  

Canada has a rigorous pharmacovigilance system designed to identify potential safety or quality concerns. Manufacturers are legally required to report adverse events, Health Canada continuously monitors safety signals, and both parties have established processes to investigate concerns and take action when warranted. This robust framework helps ensure that any potential issue is thoroughly assessed and addressed appropriately. For more information, visit Monitoring health products on the Canadian market – Canada.ca. 

###

About Organon 

Organon (NYSE: OGN) is a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. With a portfolio of over 70 products across Women’s Health, Biosimilars and General Medicines, Organon focuses on addressing health needs that uniquely, disproportionately or differently affect women, while expanding access to essential treatments in over 140 markets. For more information, visit https://www.organon.com/canada-en/ 

Source:https://www.organon.com/canada-en/wp-content/uploads/sites/5/2021/05/PROMETRIUM-PM_E.pdf